Way undervalued compared with pnv. Todays FDA approval for Symphony is enabling ARX to expand market by adding more revenue from another stream to help reduce healing time during proliferate phase like in Diabetic foot uclers and in Venous leg ulcers. Well done.
Also Myriad approval by EMA is another encouraging news. European market is ready for ARX to step in.
Two milestones in a row!
A parabolic rise of sp could be seen soon. $3.5 just makes arx matched with pnv in MC.
Great news, page-13
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
0.005(0.96%) |
Mkt cap ! $180.7M | |||
| Open | High | Low | Value | Volume |
| 52.5¢ | 53.0¢ | 52.5¢ | $25.03K | 47.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 2062 | 2 |
View Market Depth
| Last trade - 12.27pm 19/08/2024 (20 minute delay) ? |
| ARX (ASX) Chart |